
Bio-Polar
百极弘烨
Bio-Polar
Biotech/Healthcare
Baiji Hongye is a developer of innovative drugs for hematologic oncology. Through multiple R&D models—including independent innovation, collaborative development, and licensing—it pursues differentiated development of innovative drugs, aiming to create first-in-class or best-in-class Class 1 new…
Latest round: Series A (2021)
Source: ChinaBulls — chinabulls.com
Last updated 2021-10-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.